# 68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC

> **NCT06756217** · — · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DIAGNOSTIC_TEST:** 68Ga-grazytracer PET/CT

## Key facts

- **NCT ID:** NCT06756217
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06756217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06756217, "68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06756217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*